Literature DB >> 15793678

[Medicinal vasoactive therapy of microcirculation disorders in rheumatoid arthritis].

G Riemekasten1, H Schulze-Koops.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15793678     DOI： 10.1007/s00393-005-0691-y

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN： 0340-1855            Impact factor:   1.372


× No keyword cloud information.
  96 in total

Review 1.  Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease.

Authors:  Thorsten Reffelmann; Robert A Kloner
Journal:  Circulation       Date:  2003-07-15       Impact factor: 29.690

2.  Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.

Authors:  M Dziadzio; C P Denton; R Smith; K Howell; A Blann; E Bowers; C M Black
Journal:  Arthritis Rheum       Date:  1999-12

3.  The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon.

Authors:  M H Rustin; N E Almond; J A Beacham; R J Brooks; D P Jones; E D Cooke; P M Dowd
Journal:  Br J Dermatol       Date:  1987-12       Impact factor: 9.302

4.  Vascular smooth muscle cell phenotypes in primary pulmonary hypertension.

Authors:  Y Mitani; M Ueda; R Komatsu; K Maruyama; R Nagai; M Matsumura; M Sakurai
Journal:  Eur Respir J       Date:  2001-02       Impact factor: 16.671

5.  Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide.

Authors:  Evangelos Michelakis; Wayne Tymchak; Dale Lien; Linda Webster; Kyoko Hashimoto; Stephen Archer
Journal:  Circulation       Date:  2002-05-21       Impact factor: 29.690

6.  [The effect of beraprost sodium on the Raynaud's phenomenon].

Authors:  M Hiida; O Ushiyama; N Suzuki; A Ohta; K Nagasawa; M Yamaguchi
Journal:  Nihon Rinsho Meneki Gakkai Kaishi       Date:  1996-06

7.  Treatment of progressive systemic sclerosis using factor XIII.

Authors:  L Guillevin; B Chouvet; C Mery; A De Gery; J Thivolet; P Godeau; F Delbarre
Journal:  Pharmatherapeutica       Date:  1985

8.  [Treatment of systemic scleroderma with factor XIII in 86 patients, with long-term follow-up].

Authors:  L Guillevin; L Euller-Ziegler; B Chouvet; A De Gery; G Chassoux; P Lafay; G Ziegler; P Godeau; B Amor; J Thivolet
Journal:  Presse Med       Date:  1985-12-28       Impact factor: 1.228

9.  Enalapril in Raynaud's phenomenon.

Authors:  S D Janini; D G Scott; J S Coppock; P A Bacon; M J Kendall
Journal:  J Clin Pharm Ther       Date:  1988-04       Impact factor: 2.512

10.  Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis.

Authors:  Sule Apras; Ihsan Ertenli; Zeynep Ozbalkan; Sedat Kiraz; M Akif Ozturk; Ibrahim C Haznedaroglu; Veli Cobankara; Salih Pay; Meral Calguneri
Journal:  Arthritis Rheum       Date:  2003-08
View more
  2 in total

1.  [Systemic sclerosis--a challenge in rheumatology].

Authors:  P Saar; U Müller-Ladner
Journal:  Z Rheumatol       Date:  2006-09       Impact factor: 1.372

Review 2.  [Clinical risk-adapted therapies in systemic sclerosis].

Authors:  G Riemekasten; D Dragun
Journal:  Z Rheumatol       Date:  2007-12       Impact factor: 1.372
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.